BiomLogic

BiomLogic is a South Korean microbiome drug discovery company focused on developing therapeutics derived from microbial proteins and metabolites rather than using whole live microbes directly. The company was established in 2018 as a GenoFocus subsidiary dedicated to microbiome-based drug development, with a stated strategy of delivering and expressing useful microbial proteins in the gut. Its disclosed lead program is GF103, an orally delivered mutant superoxide dismutase program studied for wet age-related macular degeneration and inflammatory bowel disease. Patent and publication records also suggest work on superoxide dismutase-based approaches for mucositis and fibrotic disease. Overall, BiomLogic appears to be an early-stage private biotech centered on microbiome-enabled biologics and spore-based delivery concepts.